.png&w=3840&q=75)
Electronic Medicines Compendium. "Evorel Sequi — Summary of Product Characteristics." medicines.org.uk, www.medicines.org.uk/emc. Accessed May 2025.
Evorel Sequi
Evorel Sequi
Evorel Sequi is a sequential combined HRT patch system that delivers oestrogen and progestogen through the skin in a cyclical four-week pattern. It is designed for perimenopausal women and those in early postmenopause who have a womb, and produces a predictable monthly withdrawal bleed by mimicking the natural hormonal rhythm of the menstrual cycle.
Dr Zahra Khan
MBBS, MSc (Dist)
What is Evorel Sequi?
Evorel Sequi is a transdermal sequential HRT system consisting of two patch types used in a repeating four-week cycle. In weeks one and two, you wear an Evorel 50 patch delivering oestrogen only (50 mcg estradiol per 24 hours). In weeks three and four, you switch to an Evorel Conti patch delivering both oestrogen and progestogen (50 mcg estradiol and 170 mcg norethisterone acetate per 24 hours). The oestrogen is body identical, the progestogen is synthetic, and because both patches are transdermal, hormones bypass the liver, which is associated with a lower risk of blood clots and stroke compared to oral HRT, in line with NICE guidance.
Benefits of Evorel Sequi
Evorel Sequi restores oestrogen and provides cyclic progestogen cover, bringing meaningful relief across a wide range of menopause symptoms while maintaining a structured monthly bleeding pattern. Many women begin to notice improvement within the first few weeks, with more sustained relief established by the three-month mark.
Evorel Sequi can help to relieve the following menopause symptoms:
- Hot flushes and night sweats
- Low mood, anxiety, and irritability
- Sleep disturbance and fatigue
- Brain fog and poor concentration
- Reduced libido
- Vaginal dryness
- Joint aches and pains
- Palpitations
1 Steady hormone delivery
2 Womb protection built in
3 Predictable monthly bleeding
4 Cardiovascular considerations
5 No first-pass liver metabolism
6 Bone health protection
How to use Evorel Sequi
.png&w=3840&q=75)
Instructions for use
Evorel Sequi follows a four-week repeating cycle. Apply one Evorel 50 patch (oestrogen only) twice weekly for weeks one and two, then switch to one Evorel Conti patch (combined) twice weekly for weeks three and four. Change each patch every three to four days. Apply below the waist to clean, dry, hairless skin and rotate your site with every change.
Potential side effects of Evorel Sequi
As with all HRT, some women experience adjustment symptoms during the first weeks as your body adjusts to cyclical hormonal changes.
Understanding Evorel Sequi
Don't wait to get help.
Remember that finding the right HRT approach sometimes takes adjustment. Our clinicians are here to support you throughout your menopause journey, with regular reviews to ensure your treatment continues to work well for you.
How to get started
- 1
Answer a few questions
This is so we can best match you to a specialist who can help with any conditions and medical history.
- 2
Have your appointment
A deep, supportive conversation focused entirely on you. You’ll leave with clarity, clear next steps, and a personalised treatment plan.
- 3
Start your treatment plan
Your doctor will build a plan around you. If treatment is included, it’s delivered to your door in 2 working days, with support throughout.
Trusted by over 200,000 women in the UK for their healthcare
We have helped women take control of their health, and get back to being their best self.
¹
87%
87%
of women felt symptom relief within 8 weeks of starting their treatment
¹
97%
97%
of women agree or strongly agree, that they felt heard, listened to, and validated in their appointment¹
¹
96%
96%
of our patients said they would recommend our appointment to a friend
¹
41%
41%
of women report being in perimenopause at age 45
Citation
¹
Taken from a study conducted on our Voy menopause patients
Private care, affordable costs
We believe expert care should be accessible, without compromising on quality.
| Voy | Other clinics |
| Appointment price £99 (£145 RRP) One-time cost | Appointment price £250-£350 - Each appointment |
| Targeted treatments Scientifically proven & tailored to your individual needs | One size fits all Limited, generic treatments that neglect individual needs |
| Personalised plans From £79 per month | Personalised plans Not available |
| Unlimited free support Easy and responsive 24/5 access to your care team, unlimited video check-ins with your doctors, monitoring blood test | No support No guidance post prescription |
| Plan adjustments Your doctor will monitor your progress and adjust your treatment to maximise results | No customisation Limited monitoring and adjustment of doses, so improvement may take longer |
Meet our team of specialists
Our team is trained in perimenopause, menopause, and hormone health, with years of experience helping women
Dr Deepali Misra-SharpDoctor
Every woman’s journey is unique. My approach combines advanced expertise with compassion, offering tailored support that helps women navigate perimenopause and menopause with clarity, confidence, and renewed energy — so they can reclaim the best version of themselves.
Menopause Specialist
7083112
Dr Sarah WilsonDoctor
It’s a privilege to spend time with patients to understand their unique treatment needs and priorities and together create a management plan to address them.
Menopause specialist
GMC 6111052
Dr Cathy ArchibaldDoctor
Taking an individual approach is key to providing the best care plan for each woman and empowering personal choice.
Menopause specialist
GMC 4312576
Dr Kamilah Vidale-EllisDoctor
I am passionate about supporting women through every stage of menopause with empathy and evidence-based care, helping them feel heard and understood.
Menopause specialist
GMC 7410345
This page is provided for reference purposes only. Always follow the advice and guidance of your prescribing doctor regarding your medication and prescriptions. Do not make any changes to your medication regimen without consulting your healthcare provider.References
¹²National Institute for Health and Care Excellence. "Menopause: Diagnosis and Management." NICE Guideline NG23, updated 2024, www.nice.org.uk/guidance/ng23. Accessed May 2025.
³Vinogradova, Yana, et al. "Use of Hormone Replacement Therapy and Risk of Venous Thromboembolism: Nested Case-Control Studies Using the QResearch and CPRD Databases." BMJ, vol. 365, 2019, p. l1886, pubmed.ncbi.nlm.nih.gov/31045710.
Don't wait to get help.